INTRODUCTION
============

AD (Alzheimer\'s disease) is the most prevalent form of dementia affecting over 5.3 million people in the U.S.A. ([@B2]), and 35 million worldwide (World Health Organization). With the disproportional increase in the ageing population in the next decade, these numbers are likely to double by 2050. Although the progressive deterioration in memory and cognitive functions in AD is marked by an increase in neuronal loss and synaptic impairment in specific regions of the brain ([@B40]), the molecular mechanisms leading to the pathogenesis of the disease are still not well understood ([@B36]). Recent studies have recognized the ability of Aβ (amyloid β-peptide) to aggregate into oligomeric form and induce toxicity in neurons ([@B42]; [@B54]; [@B33]). However, understanding the mechanisms whereby Aβ oligomers impair synaptic function remains elusive.

High oxygen consumption in the brain is associated with oxidative stress, and overproduction of ROS (reactive oxygen species) is known to play an important role in the cytotoxic effects of Aβ ([@B7]; [@B51]). Recent studies have demonstrated NADPH oxidase, the superoxide producing enzyme, as an important source of ROS production in brain cells ([@B47]). Activation of NADPH oxidase is linked to excitotoxity mediated by the ionotropic glutamate receptors ([@B24]; [@B6]). Our studies further show that Aβ can also enhance ROS production in neurons via the NMDA (*N*-methyl-[d]{.smallcaps}-aspartate) receptor-dependent NADPH oxidase pathway. In turn, this receptor activation and ROS production can lead to activation of downstream signalling pathway for MAPKs (mitogen-activated protein kinases) and cPLA~2~ (cytosolic phospholipase A~2~) ([@B44]). Although the involvement in Aβ-induced neuronal dysfunction that underlies the progression of AD has not been fully investigated, there is evidence for involvement of NADPH oxidase activity in oxidative and inflammatory responses in a number of neurodegenerative diseases ([@B52]).

Despite the increasing recognition of a link between oligomeric Aβ and NMDA receptor function, the extent of neuronal damage due to prolonged exposure of neurons to this toxic form of Aβ has not been investigated in detail. In the present study, we investigated the effects of oligomeric Aβ on rat primary cortical neurons and determined that prolonged exposure of neurons to oligomeric Aβ led to accumulation of NADPH oxidase-dependent ROS production, and in turn mitochondrial dysfunction, NMDA receptor-mediated Ca^2+^ influx and AA (arachidonic acid) release. We further demonstrated that EGCG \[(−)-epigallocatechin-3-gallate\], a major polyphenol from green tea, can protect neurons from the cytotoxic effects of oligomeric Aβ.

MATERIALS AND METHODS
=====================

Materials
---------

DMEM (Dulbecco\'s modified Eagle\'s medium), Neurobasal medium, Pen/Strep, B27-AO (B27 without antioxidants), [l]{.smallcaps}-glutamine, Hepes, Ham\'s F-12 medium, 10×Hanks buffer, Fluo-4 AM, AlarmaBlue™ and trypsin-EDTA were obtained from Invitrogen (Carlsbad, CA, U.S.A.). BCS (bovine calf serum) was purchased from Hyclone (Thermo Fisher Scientific, South Logan, UT, U.S.A.). DHE (dihydroethidium), NMDA, resveratrol, EGCG, poly-[l]{.smallcaps}-lysine, BSA and nimopridine were purchased from Sigma--Aldrich (St. Louis, MO, U.S.A.). \[1-^14^C\]AA (specific activity 50 mCi/mmol) was obtained from NEN (Boston, MA, U.S.A.). Aβ (Aβ~1-42~ and Aβ ~42-1~) was purchased from American Peptide Co. (Sunnyvale, CA, U.S.A.). MnTBAP \[Mn(III)-tetrakis(4-benzoic acid)-porphyrin chloride\] was obtained from EMD Chemicals Inc. (Darmstadt, Germany). The NADPH oxidase inhibitor, gp91ds-tat peptide that specifically targets the gp91 docking site, was originally designed by the Pagano group ([@B37]) and was synthesized by Anaspec (San Jose, CA, U.S.A.).

Primary cortical neuron cultures
--------------------------------

Primary cortical neurons were prepared from fetal brain of Sprague--Dawley rats at E17 (embryonic day 17) using the instructions described previously ([@B44]) with slight modifications. In brief, cerebral cortices were dissected in Hanks buffer followed by incubation with 0.05% trypsin (GIBCO, Grand Island, NY, U.S.A.) at 37°C for 45 min. The cortices were mechanically dispersed with a pasture pipette. The cell pellet was re-suspended in D10C medium (DMEM including 10% BCS, 10% Ham\'s F-12 medium, 2 mM [l]{.smallcaps}-glutamine, 2.5% Hepes and 0.25% Pen/Strep). Cells (1.3×10^5^/cm^2^) were seeded into 50 mg/l poly-[l]{.smallcaps}-lysine-coated plates or dishes in D10C medium. After 4--5 h, the D10C medium was replaced with Neurobasal medium containing 2% B27-AO, 2 mM [l]{.smallcaps}-glutamine and 1% Pen/Strep. Cells were cultured at 37°C in a humidified incubator with 5% CO~2~ for at least 8 days before experiments, and half of the medium was replaced with fresh medium every 3--4 days. Immunostaining for specific markers of astrocytes \[GFAP (glial fibrillary acidic protein)\], microglia (OX-42) and neurons \[MAP-2 (microtubule-associated protein-2)\] indicated that the 8-day-old neuronal cultures contained only 3--4% astrocytes and 3% microglia ([@B44]). Neuronal morphology was routinely visualized using an inverted microscope from Olympus (Center Valley, PA, U.S.A.) with a ×20 objective. Experiments were carried out according to the guidelines set forth by the NIH Guide for the Care and Use of Laboratory Animals.

Preparation and characterization of A**β**
------------------------------------------

### Preparation of oligomeric Aβ

Oligomeric Aβ, referred to as Aβ~1-42~, was prepared as described ([@B11]). Briefly, purified Aβs (America Peptide) were dissolved in HFIIP (1,1,1,3,3,3-hexafluoro-2-propanol) to allow full conversion into the monomeric form. The monomeric Aβ was divided into aliquots into Eppendorf tubes and the organic solvent was evaporated using a speed vacuum apparatus (Savant, Fisher Scientific, St. Louis, MO, U.S.A.). The dried Aβ was stored at −80°C until used. To obtain oligomeric Aβ, samples in the Eppendorf tubes were dissolved in DMSO to make a concentration of 5 mM, followed by sonication for 30 s. The suspension was diluted with PBS (pH 7.4) to 0.1 mM Aβ, and the samples were then incubated at 4°C for 24 h. As a control, Aβ~42-1~ was treated similarly to Aβ~1-42~.

### Analysis of oligomeric Aβ species

Samples were mixed with 2×Tris-tricine buffer (Bio-Rad, Hercules, CA, U.S.A.) and resolved in a 16% Tris-tricine gel. After electrophoresis, samples were transferred to PVDF membrane with a 200 mA current at 4°C for 2 h. The membrane was incubated with 5% non-fat milk in TBS-T (Tris-buffered saline, pH 7.4, with 0.5% Tween 20) at room temperature (25°C) for 1 h. The blot was then reacted with antibodies for Aβ, 6E10 (1:1000; Covance, CA, U.S.A.), overnight at 4°C. After washing three times with TBS-T, the membrane was incubated with goat anti-mouse IgG-horseradish peroxidase (1:5000; Sigma--Aldrich) for 1 h at room temperature, and further washed three times with TBS-T. Immunolabelling was detected by chemiluminescence (SuperSignal West Pico, Pierce, Rockford, IL, U.S.A.).

Methods for assessing neuronal viability
----------------------------------------

### Assessment of mitochondrial function

Mitochondrial dysfunction is an initial step in apoptotic pathways that lead to neuronal cell death. In the present study, mitochondrial function was assessed by the ability of reductase in neurons to reduce MTT \[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2*H*-tetrazolium bromide; Sigma--Aldrich\]. In brief, primary cortical neuron cultures in 24-well plates were treated with Aβ and/or inhibitors at 37°C for different times. After treatment, the culture medium was replaced by 500 μl of neurobasal medium with 0.5 mg/ml MTT, and further incubated at 37°C for 3 h. After removing the MTT solution, the remaining formazan crystals were dissolved in 500 μl of DMSO. After shaking the plates at room temperature for 5 min, absorbance was read at 540 nm using a Syn4 Plate Reader (BioTek Instruments, Inc, Fisher Scientific, St. Louis, MO, U.S.A.).

### Assessment of neuronal membrane integrity

The release of the soluble enzyme, LDH (lactate dehydrogenase), from cells into the culture medium is an indication of loss of membrane integrity. In this assay, neurons were cultured in 24-well plates and treated with 1 μM Aβ at 37°C for 24 h. After treatment, an aliquot of the culture medium was collected and LDH activity was measured using the LDH kit (Roche, Indianapolis, IN, U.S.A.).

### AlamarBlue assay

AlamarBlue™ (Invitrogen) is a cell permeable non-fluorescent dye, which can be converted into to red fluorescence via reductive reactions within live cells. This assay is used to determine the extent of cell viability in cultures after various treatments. Briefly, neurons were cultured in 24-well plates for 9 days and then treated with or without 1 μM Aβ at 37°C for 24 h. After treatments, 100 μl of AlamarBlue™ was added to each well and neurons were further incubated at 37°C for 3--4 h. Absorbance was read at 570 nm with measurement at 600 nm as a reference.

Determination of NMDA-induced Ca^2+^ influx
-------------------------------------------

NMDA-induced Ca^2+^ influx in neurons was determined using the calcium fluorescent dye, Fluo-4 AM, and performed according to the instructions described previously ([@B15]). Briefly, neurons were cultured on 12 mm coverslips for 9--10 days. Before stimulation with NMDA, neurons were treated with or without 1 μM Aβ and/or 10 μM EGCG or 1 μM gp91ds-tat for 30 min or 16 h. After pre-treatment, cells were incubated at room temperature (in the dark) with 1 μM Fluo-4 AM for 30 min in ACSF (artificial cerebrospinal fluid) medium (125 mM NaCl, 10 mM Hepes, 5 mM KCl, 3.1 mM CaCl~2~, 1.3 mM MgCl~2~ and 10 mM glucose, pH 7.4). Cells were then transferred to a flow through a chamber fitted within the microscope. Time-lapse Ca^2+^ imaging was performed using an upright wide-field epi-fluorescence microscope (FN1 system, Nikon) with a ×40/0.8 water immersion objective. Excitation was generated with an X-Ford metal halide lamp filtered with a fluo-4 filter cube. Emission was detected by a CoolSNAP-EZ CCD-camera (Photometrics, AZ, U.S.A.). After perfusion to obtain the base-line results, 50 μM NMDA was applied in ACSF medium without MgCl~2~ but with 1 μM nimopridine, a selective antagonist of the L-voltage-sensitive calcium channel ([@B18]; [@B53]). The perfusion system was equipped with a pinch valve that controls the duration of the application. After exposing neurons to NMDA for 30 s, cells were perfused again with the ACSF medium with MgCl~2~ (1.3 mM). During perfusion, images of neurons were acquired using the Metamorph software (Molecular Devices, Sunnyvale, CA, U.S.A.) at 2 s intervals for 2 min (a total of 61 frames were obtained). Each treatment condition was performed in triplicate and three random fields were recorded. Results were exported using the Metamorph software to generate background-subtracted images. The magnitude of the Ca^2+^ signal was defined as the average of Δ*F*/*F*~0~ from each cell and the area under the curve for NMDA stimulation and ACSF washout was determined using the GraphPad Prism Software (GraphPad Prism Software Inc., San Diego, CA, U.S.A.). At least 100 cells were selected to obtain the average area for each group.

Measurement of ROS production
-----------------------------

ROS production in primary cortical neurons was assayed using DHE. Oxidation of DHE by superoxide anions produces fluorescent ethidium, which is intercalated into DNA ([@B9]). Therefore ROS production can be quantified by measuring the fluorescence intensity of ethidium in cells. In brief, neurons were cultured (to 70% confluence) on 35 mm dishes coated with 50 mg/l poly-[l]{.smallcaps}-lysine. Neurons were then treated with Aβ, EGCG, gp91ds-tat or MnTBAP for 30 min or 16 h in neurobasal medium without Phenol Red but with 0.5 mg/ml BSA. At 30 min before image acquisition, cells were loaded with 10 μM DHE and incubated at 37°C. Fluorescence images were acquired using a Nikon TE-2000 U inverted microscope with a ×20 NA 0.95 objective and a cooled CCD camera controlled with a computer running the MetaView imaging software (Universal Imaging, West Chester, PA, U.S.A.). The fluorescence excitation source was controlled with a Uni-Blitz mechanical shutter. For image acquisition, a short exposure time (200 ms) and low-intensity excitation light were applied to minimize photo-bleaching. Digital images were analysed using the MetaView software with automatic background subtraction. Threshold fluorescence was obtained for each image before the quantification. For each field, the total fluorescence was measured and expressed as average fluorescence versus total number of cells (recorded as bright field image). For each treatment group, three random images from the same field were taken and analysed, and each treatment was repeated three times independently for statistical analysis.

Measurement of AA release
-------------------------

Measurement of AA release was performed essentially as previously described ([@B55]; [@B44]) with minor modifications. Briefly, primary cortical neurons in a 35-mm dish were treated with or without 1 μM Aβ for different times (0, 4, 12 and 24 h) at 37°C and 0.1 μCi of \[1-^14^C\]AA was added for the final 4 h. This time is sufficient for more than 75% of the \[1-^14^C\]AA to be incorporated into membrane phospholipids ([@B55]). After incubation, excess free \[1-^14^C\]AA in the cells and medium was removed by three successive washes with buffer A containing 145 mM NaCl, 5.5 mM KCl, 1.1 mM MgC1~2~, 1.1 mM CaC1~2~, 5.5 mM glucose, 20 mM Hepes, pH 7.4 and BSA (0.5 mg/ml). The phospholipid-labelled neurons were stimulated with 100 μM NMDA at 37°C for 30 min, and the release of \[1-^14^C\]AA into the culture medium was determined with a Beckman LS 5800 liquid scintillation counter (Fullerton, CA, U.S.A.). Radioactivity remaining in the cells was also determined by adding 2 ml of methanol to the dish and harvesting the cells using a scraper. Net radioactivity released into the culture medium in response to NMDA was obtained by subtracting the background radioactivity released from cells incubated in the absence of NMDA. Labelled AA released from neurons treated with Aβ for different time periods and subsequently subjected to a 30-min stimulation with NMDA were expressed as percentages of the total radioactivity in labelled cells, i.e. radioactivity released into the medium over 30 min plus radioactivity remaining in the cells.

Statistical analysis
--------------------

The results were analysed either by one-way or two-way ANOVA followed by Bonferroni\'s multiple comparison tests (V4.00, GraphPad Prism Software, Inc, San Diego, CA, U.S.A.). Values of *P*\<0.05 were considered significant.

RESULTS
=======

Prolonged exposure of neurons to oligomeric Aβ induces mitochondrial dysfunction but not neuronal cell death
------------------------------------------------------------------------------------------------------------

In the present study, we prepared oligomeric Aβ according to the instructions described by LaDu\'s group ([@B11]). Western-blot analysis of the preparation showed the presence of monomers, trimers and tetramers, but no obvious dimers or higher-molecular mass oligomers ([Figure 1A](#F1){ref-type="fig"}). To test whether the time of Aβ aggregation affects neuronal toxicity, Aβ was aggregated at 4°C for 0, 4, 12 or 24 h before exposure to rat primary cortical neurons and further incubation at 37°C for 24 h. Results in [Figure 1(B)](#F1){ref-type="fig"} show a time-dependent decrease in mitochondrial function (i.e. MTT reduction) with increase in time of Aβ aggregation. Significant decrease in MTT was observed after exposing neurons to Aβ (1 μM) that was aggregated for 12 (*P*\<0.05) and 24 h (*P*\<0.001).

![Neuronal toxicity of oligomeric Aβ\
Oligomeric Aβ was prepared as indicated in the Materials and methods section. (**A**) The sample from a typical preparation was analysed by Western blot showing the presence of trimers and tetramers as well as monomers after aggregation in PBS at 4°C for 24 h. Positions of molecular mass markers are shown on the left in kDa. (**B**) Aβ was aggregated for different time periods (0, 4, 12 and 24 h) at 4°C and then 1 μM was incubated with rat primary cortical neurons for 24 h. Results depict mitochondrial function using the MTT assay. (**C**) Neurons were treated with or without Aβ (1 μM) for 24 h followed by assay of LDH release as an indication of a loss in membrane integrity. (**D**) Neurons were treated with or without oligomeric Aβ (1 μM) for 24 h and neuronal viability was determined using the AlarmaBlue™ assay. (**E**) Rat primary cortical neurons were incubated with or without oligomeric Aβ~1-42~ (1 μM) or Aβ~42-1~ (1 μM) for 0, 8, 16 or 24 h, and mitochondrial function was measured using the MTT assay. Results are mean±S.E.M. values for three independent experiments and are analysed by one-way ANOVA followed by Bonferroni\'s multiple comparison tests.\**P*\<0.05 and \*\*\**P*\<0.001, as compared with control.](an003e050f01){#F1}

Following the study with MTT reduction to access mitochondrial function, we also determined whether exposure of neurons to oligomeric Aβ (1 μM) is associated with an increase in cell death. LDH release was used to determine loss of membrane integrity, and AlamarBlue™ assay was used to determine neuronal viability. As shown in [Figures 1(C)](#F1){ref-type="fig"} and [1(D)](#F1){ref-type="fig"}, incubation of neurons with oligomeric Aβ (1 μM) for 24 h neither caused an increase in LDH release nor changes in live cell numbers. These results indicate that despite mitochondrial dysfunction, Aβ-treated neurons remain viable.

The specificity for Aβ~1-42~ for mediating mitochondrial dysfunction was tested by comparing with the reverse peptide, Aβ ~42-1~, which was prepared using the same instruction as Aβ~1-42~. As shown in [Figure 1(E)](#F1){ref-type="fig"}, neurons exposed to Aβ~42-1~ (1 μM) did not result in mitochondrial dysfunction and MTT levels were comparable with controls without Aβ.

Prolonged exposure of neurons to oligomeric Aβ inhibits NMDA-induced Ca^2+^ influx
----------------------------------------------------------------------------------

Since prolonged exposure of neurons to oligomeric Aβ resulted in mitochondrial dysfunction but not cell death, we next examined whether this form of Aβ can alter other neuronal functions, such as NMDA receptor-mediated Ca^2+^ influx. In the present study, primary cortical neurons were loaded with Fluo-4 AM and perfused with NMDA (50 μM) for 30 s. As shown in [Figure 2(A)](#F2){ref-type="fig"}, NMDA stimulation elicited a rapid and transient increase in Ca^2+^ influx. However, when neurons were exposed to oligomeric Aβ (1 μM) for 16 h before stimulation with NMDA, a significant decrease (57%, *P*\<0.05) in Ca^2+^ influx was observed ([Figure 2A](#F2){ref-type="fig"}). Representative images of neurons taken at the time of NMDA stimulation also showed a decrease in fluorescence between neurons pre-treated with Aβ for 16 h as compared to controls ([Figure 2B](#F2){ref-type="fig"}). As a negative control, neurons treated with Aβ~42-1~ (1 μM) for 16 h exhibited no significant changes in NMDA-induced Ca^2+^ influx, as compared with untreated controls ([Figure 2C](#F2){ref-type="fig"}). These results indicate that impairment of NMDA receptor-mediated Ca^2+^ influx is associated with prolonged exposure of neurons to oligomeric Aβ.

![Prolonged exposure of neurons to Aβ impairs NMDA receptor-mediated Ca^2+^ influx\
Primary cortical neurons were cultured on coverslips and exposed to oligomeric Aβ~1-42~ (1 μM) or Aβ~42-1~ (1 μM) for 16 h. Neurons were labelled with Fluo-4-AM for 30 min before stimulation with NMDA (50 μM) for 30 s in ACSF medium containing nimopridine (1 μM) without Mg^2+^, and then followed by perfusion with ACSF medium with Mg^2+^. Average fluorescence of Fluo-4 was measured as described in the Materials and methods section. (**A**) Representative curves depicting NMDA-induced Ca^2+^ influx with or without oligomeric Aβ for 16 h. (**B**) Representative fluorescent images of neurons taken before and during (30 s) NMDA stimulation. (**C**) Bar graphs to depict NMDA-induced Ca^2+^ influx as determined by calculating the area under the curve using the GraphPad Prism Software 4. Results are means±S.E.M. for three independent experiments and are analysed by one-way ANOVA followed by Bonferroni\'s multiple comparison tests.\* *P*\<0.05, as compared with control.](an003e050f02){#F2}

Prolonged exposure of neurons to oligomeric Aβ decreases NMDA-induced AA release
--------------------------------------------------------------------------------

We previously reported that Aβ causes AA release from neurons through a signalling pathway involving NMDA receptor, NADPH oxidase, ERK1/2 (extracellular-signal-regulated kinase 1/2) and cPLA~2~ ([@B44]). In the present study, we examined the effect of prolonged exposure of neurons to oligomeric Aβ on NMDA-induced AA release. Cortical neurons were pre-treated with or without Aβ (1 μM) for different time periods (0--24 h) and labelled with \[1-^14^C\]AA for the final 4 h before stimulation with NMDA (100 μM) for 30 min. As shown in [Figure 3](#F3){ref-type="fig"}, a significant (*P*\<0.05) decrease in the NMDA-induced AA release from prelabelled-phospholipids was observed on exposure of neurons to oligomeric Aβ for 12 or 24 h. As a negative control, no obvious decrease in AA release was observed on incubation of neurons with the reverse peptide (Aβ~42-1~) (results not shown). These results are consistent with results in [Figure 2](#F2){ref-type="fig"} showing that prolonged Aβ exposure to neurons inhibited NMDA-stimulated Ca^2+^ influx.

![Prolonged exposure of neurons to Aβ inhibits NMDA receptor-mediated AA release\
Neurons were treated with Aβ (1 μM) for 0, 4, 12 and 24 h, and subsequently labelled with \[1-^14^C\]AA for the final 4 h. After removing free \[1-^14^C\]AA, neurons were stimulated with NMDA (100 μM) for 30 min and \[1-^14^C\]AA release from phospholipids into the medium was measured after subtracting background release. Results are means±S.E.M. for three independent experiments and are analysed by one-way ANOVA followed by Bonferroni\'s multiple comparison tests; \**P*\<0.05 and \*\**P*\<0.01, as compared with control.](an003e050f03){#F3}

Prolonged exposure of neurons to Aβ increases ROS production
------------------------------------------------------------

In our earlier study, although NMDA (100 μM) could cause a robust increase in ROS production in neurons, the amount of ROS produced by Aβ (1-5 μM) was very low ([@B44]). In this next set of experiments, we determined levels of ROS in neurons after prolonged exposure to Aβ. As shown in [Figures 4(A)](#F4){ref-type="fig"} and [4(B)](#F4){ref-type="fig"}, a significant increase (*P*\<0.01) in ROS production was found in neurons on exposure to oligomeric Aβ (1 μM) for 16 h. Examination of neurons under the bright field microscope indicated that neuronal morphology was preserved after prolonged exposure to Aβ ([Figure 4A](#F4){ref-type="fig"}).

![Prolonged exposure to Aβ induces ROS accumulation in neurons\
(**A**) Neurons were pre-treated with Aβ (1 μM) for 30 min or 16 h, and then loaded with DHE. In each field, DHE fluorescent neurons and the corresponding bright field images were recorded. (**B**) Average fluorescent intensity of neurons was calculated. Results are means±S.E.M. for three independent experiments and analysed by one-way ANOVA followed by Bonferroni\'s multiple comparison tests. \*\**P*\<0.01 as compared with control.](an003e050f04){#F4}

Gp91ds-tat protects neurons from prolonged Aβ-induced ROS production, mitochondrial dysfunction and inhibition of NMDA-mediated Ca^2+^ influx
---------------------------------------------------------------------------------------------------------------------------------------------

Since prolonged exposure of neurons to oligomeric Aβ is associated with ROS accumulation, we subsequently evaluated the source of ROS using the cell permeable NADPH oxidase peptide inhibitor, gp91ds-tat. Results in [Figure 5(A)](#F5){ref-type="fig"} show that ROS accumulation due to prolonged exposure of Aβ (1 μM) was completely inhibited by pre-treatment of neurons with gp91ds-tat (1 μM). These results suggest that NADPH oxidase is the primary source of ROS in neurons induced by Aβ.

![NADPH oxidase inhibitor, gp91ds-tat, inhibits ROS production and protects neurons against Aβ-induced cytotoxicity\
(**A**) Rat primary cortical neurons were treated with gp91ds-tat (1 μM) for 30 min before exposure to Aβ (1 μM) for 16 h and followed by ROS determination as described for [Figure 4](#F4){ref-type="fig"}. Results represent the average fluorescent intensity of DHE in neurons and are means±S.E.M. for three independent experiments. Two-way ANOVA revealed a significant interaction (*P* = 0.0072) and significant effects of Aβ (*P* = 0.0039) and gp91ds-tat (*P* = 0.0180). Bonferroni post-tests showed a significant difference between control and Aβ (\*\**P*\<0.01) and between Aβ treatment without versus with gp91ds-tat (∧*P*\<0.05). (**B**) Neurons were treated with gp91ds-tat (1 μM) for 30 min before exposure to Aβ (1 μM) for 16 h followed by the MTT assay. Results are means±S.E.M. for three independent experiments. Two-way ANOVA revealed a significant interaction (*P* = 0.0320) and significant effects of Aβ (*P* = 0.0160) and gp91ds-tat (*P* = 0.0433). Bonferroni post-tests showed a significant difference between control and Aβ (\**P*\<0.05) and between Aβ treatment without versus with gp91ds-tat (∧*P*\<0.05). (**C**) Neurons were incubated with gp91ds-tat (1 μM) for 30 min before exposure to Aβ (1 μM) for 16 h, and NMDA (50 μM)-induced Ca^2+^ influx was determined as described in [Figure 2](#F2){ref-type="fig"} Results are means±S.E.M. for three independent experiments. Two-way ANOVA revealed a significant interaction (*P* = 0.0167) and significant effects of Aβ (*P* = 0.0095) and gp91ds-tat (*P* = 0.0027). Bonferroni post-tests showed a significant difference between control and Aβ (\**P*\<0.05) and between Aβ treatment without versus with gp91ds-tat (ˆˆ*P*\<0.01).](an003e050f05){#F5}

We further tested whether gp91ds-tat can protect neurons from the toxic effects of prolonged exposure to oligomeric Aβ. As shown in [Figure 5(B)](#F5){ref-type="fig"}, pre-treatment of neurons with gp91ds-tat completely prevented Aβ-induced mitochondrial dysfunction. Pretreatment with gp91ds-tat also protected neurons from Aβ-induced inhibition of NMDA receptor-mediated Ca^2+^ influx ([Figure 5C](#F5){ref-type="fig"}).

EGCG from green tea inhibits the neurotoxic effects of Aβ
---------------------------------------------------------

Since inhibitors of NADPH oxidase-mediated ROS production can protect neurons from the toxic effects of Aβ, it is reasonable that other natural antioxidants may also inhibit Aβ-induce neurotoxicity. Therefore our experiment was extended to testing botanical polyphenols known to possess anti-oxidative properties. Results show that exposing neurons to EGCG (10 μM), an antioxidant from green tea, completely prevented mitochondrial dysfunction induced by 1 μM Aβ ([Figure 6A](#F6){ref-type="fig"}). Incubation of neurons for 16 h with EGCG alone (up to 100 μM) had no effect on mitochondrial function (results not shown). Albeit not as effective as EGCG, resveratrol (25--50 μM), another polyphenol enriched in grapes, could also inhibit Aβ-induced mitochondrial dysfunction in neurons (results not shown).

![EGCG protects neurons against Aβ-induced cytotoxicity\
(**A**) Rat primary cortical neurons were treated with EGCG (10 μM) for 30 min before exposure to Aβ (1 μM) for 16 h, and followed by determination of mitochondrial function using the MTT assay. Results are means±S.E.M. for three independent experiments. Two-way ANOVA revealed a significant interaction (*P* = 0.0139), and significant effects of Aβ (*P* = 0.0149) and EGCG (*P* = 0.0172). Bonferroni post-tests showed a significant difference between control and Aβ (\*\**P*\<0.01) and between Aβ treatment without versus with EGCG (∧*P*\<0.05). (**B**) Neurons were incubated with EGCG (10 μM) for 30 min before exposure to Aβ (1 μM) for 16 h, followed by determination of NMDA-induced Ca^2+^ influx as described in [Figure 2](#F2){ref-type="fig"}. Analysis by two-way ANOVA revealed a significant interaction between EGCG and Aβ (*P* = 0.032), and a significant effect of Aβ (*P* = 0.027). Bonferroni post tests showed a significant difference between control and Aβ (\**P*\<0.05). (**C**) Neurons were treated with EGCG (10 μM) or MnTBAP (20 μM) for 30 min before exposure to Aβ (1 μM) for 16 h, followed by determination of ROS as described in [Figure 4](#F4){ref-type="fig"}. Results are means±S.E.M. for three independent experiments. Two-way ANOVA revealed a significant interaction between Aβ and EGCG (*P* = 0.0109), and significant effects of Aβ (*P* = 0.0075) and EGCG (*P* = 0.0184). A significant interaction between Aβ and MnTBAP (*P* = 0.0183) was also found. Bonferroni post-tests showed a significant difference between control and Aβ (\*\**P*\<0.01) and between Aβ treatment without versus with EGCG or MnTBAP (ˆˆ*P*\<0.01).](an003e050f06){#F6}

Since prolonged exposure of neurons to Aβ resulted in inhibition of NMDA-induced Ca^2+^ influx ([Figure 2](#F2){ref-type="fig"}), we further tested whether pre-treatment of neurons with EGCG could prevent this deleterious effect. As shown in [Figure 6(B)](#F6){ref-type="fig"}, pre-treatment of neurons with 10 μM EGCG completely blocked the inhibition of NMDA-induced Ca^2+^ influx caused by prolonged exposure to 1 μM Aβ for 16 h. EGCG alone exerted no significant effect on NMDA-induced Ca^2+^ influx, as compared to untreated control ([Figure 6B](#F6){ref-type="fig"}).

Results in [Figure 4](#F4){ref-type="fig"} demonstrated that prolonged Aβ exposure caused ROS accumulation in neurons. It was therefore important to determine whether EGCG may play a role in inhibiting Aβ-mediated ROS production. [Figure 6(C)](#F6){ref-type="fig"} showed that pre-treatment with EGCG (10 μM) before exposing neurons to Aβ (1 μM) for 16 h completely prevented Aβ-induced ROS production. As a positive control, MnTBAP (20 μM), a compound widely used as an SOD (superoxide dismutase) mimetic ([@B8]) and ROS scavenger ([@B14]), also inhibited ROS production induced by Aβ exposure for 16 h ([Figure 6C](#F6){ref-type="fig"}). On the other hand, neither EGCG nor MnTBAP alone could alter basal ROS levels in neurons ([Figure 6C](#F6){ref-type="fig"}).

DISCUSSION
==========

Despite the fact that AD was discovered over 100 years ago, the pathogenesis of the disease is still not well understood and effective treatment for the disease remains elusive. Although many studies in the past regarded amyloid accumulation to be a pathological landmark of the disease, the 'amyloid hypothesis' has been subjected to challenges ([@B16]). A major problem regarding this hypothesis is the inability to link amyloid accumulation to the severity of the disease, and difficulty in demonstrating toxic forms of Aβ in AD brain. Nevertheless, recent studies have provided convincing evidence that Aβ aggregates, especially when present in the oligomeric forms, can alter neuronal circuitry and impair synaptic activity, events that underlie the cognitive decline in AD ([@B33]). Work by Shankar\'s group further demonstrated the release of soluble Aβ oligomers (mainly dimers and trimers) from hippocampal slices of AD transgenic mice, and that low concentrations of the Aβ oligomers in the conditioned media can cause neurotoxic effects and inhibit NMDA-induced Ca^2+^ influx into synaptic spines ([@B42], [@B43]). With regard to the presence of Aβ oligomers in the AD brain, a recent study provided strong support for the progressive accumulation of these toxic forms of Aβ with increasing degree of synaptic loss and severity of cognitive impairment ([@B35]). It is obvious that different types of tissue or cell preparations can produce different patterns of Aβ oligomers, leading to different magnitude of toxicity. In fact, different ratios of Aβ~1-42~ to Aβ~1-40~ can offer different patterns of aggregation kinetics and elicit different degrees of neurotoxicity ([@B27]). In the present study, aggregation of synthetic Aβ using the instruction described by LaDu\'s group was shown to produce trimers and tetramers, with no obvious presence of dimers or higher-molecular-mass oligomers ([@B11]; [@B49]). As discussed in a recent review by [@B50], Aβ oligomer aggregation pattern may vary depending on acidity and the ionic strength of the solvent used ([@B50]). In our hands, this instruction for Aβ aggregation has consistently produced oligomers that impair mitochondrial function in neurons, as demonstrated using the MTT assay. However, despite the decrease in mitochondrial function, exposure to 1 μM oligomeric Aβ for 24 h did not result in neuronal cell death or change in membrane integrity ([Figure 1](#F1){ref-type="fig"}). In line with the progressive nature of AD, it is not surprising that Aβ oligomers produce subtle neurotoxic effects that progress to full impairment of synaptic plasticity and cognitive function before cell death ([@B39]).

Several earlier studies have demonstrated the ability of oligomeric Aβ to exert cytotoxic effects on neurons. Aβ was shown to suppress NMDA-induced currents in cortical neurons, and this effect was attributed in part to alteration of signalling pathways leading to endocytosis of NMDA receptors ([@B46]). Other studies showed an interaction between oligomeric Aβ and the NMDA receptor trafficking pathway in neurons, and in turn resulting in alterations of intracellular Ca^2+^ homoeostasis ([@B54]). Aβ oligomers can cause Ca^2+^ influx due to stimulation of NMDA and AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptors, and this type of glutamate receptor-induced excitotoxicity can stimulate downstream pathways leading to mitochondrial membrane dysfunction and neuronal cell death ([@B1]). Indeed, dysregulation of Ca^2+^ homoeostasis is an important consequence of amyloid toxicity ([@B13]; [@B34]).

Studies *in vivo* and *in vitro* have demonstrated that neuronal excitotoxic events, such as NMDA receptor activation, are linked to ROS production through activation of NADPH oxidase ([@B24]; [@B44]; [@B6]). In a study with hippocampal slices, ROS from NADPH oxidase was shown to activate signalling pathways leading to the activation of ERK1/2 ([@B41]). Since ERK1/2 is an important kinase for phosphorylation of cPLA~2~, it is reasonable that oligomeric Aβ can induce activation of cPLA~2~ and the subsequent release of AA ([@B44]). cPLA~2~ can perturb membrane phospholipids, and besides being a precursor for the synthesis of eicosanoids, AA is an important lipid mediator for regulation of multiple signalling pathways ([@B4]). In the present study, prolonged Aβ exposure to neurons results in the decrease in NMDA receptor activity and AA release ([Figure 3](#F3){ref-type="fig"}). These results lend further support to the ability of oligomeric Aβ to impair a variety of neuronal functions ([@B45]). The ability of oligomeric Aβ to inhibit NMDA receptor function may also be due to a number of other factors. Besides modulation of receptor endocytosis ([@B46]), there is evidence that Aβ may bind directly to the NMDA receptor subunits ([@B12]; [@B39]). Although the mechanism whereby prolonged Aβ exposure impairs NMDA receptor response is not yet clearly understood, our results with an gp91ds-tat clearly demonstrate the important role of NADPH oxidase and ROS in mediating the damaging effects elicited by Aβ.

AD pathology is associated with an increase in mitochondrial abnormalities and a decrease in ATP production ([@B17]; [@B31]). In fact, oxidatively modified proteins are found in mitochondria ([@B51A]), and increased levels of oxidative stress marker proteins and lipids, such as protein carbonyls, 3-nitrotyrosine, hydroxynonenal and isoprostanes, are found in MCI (mild cognitive impairment) brains ([@B22]; [@B30]). Whether subunits of NMDA receptors are particularly susceptible to these oxidative effects remains to be investigated. Furthermore, despite evidence for soluble Aβ to cross the cell membrane and to directly interact with mitochondrial enzymes, the mechanism underlying mitochondrial dysfunction is not yet fully understood ([@B56]; [@B25]). Studies with neurons and astrocytes have demonstrated activation of cPLA~2~ by oligomeric Aβ and, subsequently, this leads to alteration of mitochondrial membrane ([@B26]; [@B57]). ROS are small molecules with important pleiotropic functions. Besides regulating MAPK activity, ROS can perturb membrane lipids and alter membrane proteins. Therefore the increase in ROS production due to prolonged exposure of neurons to Aβ can be an important underlying mechanism for explaining the oxidative-induced impairment in synaptic function in AD ([@B39]).

Another important finding from this study is the ability of botanical antioxidants to protect neurons from the cytotoxic effects of oligomeric Aβ. Our results show that EGCG from green tea is particularly effective in inhibiting ROS, and protects neurons from Aβ-induced inhibition of NMDA-stimulated Ca^2+^ influx and mitochondrial dysfunction. Indeed, a number of studies have demonstrated EGCG to elicit neuroprotective effects ([@B10]; [@B23]; [@B38]; [@B29]; [@B21]; [@B28]), and to protect neurons against Aβ-induced toxicity ([@B3]). EGCG is readily soluble and can cross the blood--brain barrier ([@B29]). In animal studies, long-term oral administration of 0.05% or 0.1% EGCG in drinking water (for 6 months) to SAMP8 (senescence-accelerated mice prone-8) mice could decrease levels of Aβ in the hippocampus and improve learning and memory ([@B28]). In cultured hippocampal neurons, EGCG increased neuronal survival after a 48-h exposure to Aβ and this effect was associated with a decrease in the level of MDA (malondialdehyde), a marker for lipid peroxidation ([@B10]). In our study, EGCG up to 100 μM exerted no toxic effects in neurons, and 10 μM of EGCG was already sufficient to protect neurons from Aβ-induced neurotoxicity ([Figure 5](#F5){ref-type="fig"}). Besides inhibition of Aβ-induced toxicity, there is evidence suggesting multiple effects of EGCG, including inhibition of BACE1 (β-secretase) ([@B20]) and aggregation or remodelling of Aβ oligomers ([@B32]; [@B3]). An *in vitro* study with 7PA2 cells demonstrated that EGCG can convert Aβ oligomers into non-toxic spherical assemblies ([@B5]). In transgenic mice overexpressing human APPsw, EGCG increased α-secretase activity and enhanced the production of non-amyloidogenic APP-α (amyloid precursor protein-α) as opposed to the cytotoxic Aβ ([@B38]). Other studies with endothelial cells and astrocytes have demonstrated that EGCG inhibits NADPH oxidase activity ([@B48]; [@B19]).

In summary, results from this study demonstrated impairment of neuronal function on prolonged exposure to oligomeric Aβ. As shown in [Figure 7](#F7){ref-type="fig"}, short-term exposure of Aβ to neurons can cause excitatory events including activation of NMDA receptor, increase in Ca^2+^ influx, ROS production and stimulation of signalling pathways leading to the activation of cPLA~2~ and AA release ([@B44]). In the present study, we show that more ROS is produced on prolonged exposure to Aβ and this event is accompanied by impairment of NMDA-mediated Ca^2+^ influx and AA release, and mitochondrial dysfunction ([Figure 7](#F7){ref-type="fig"}). Since ROS production on prolonged exposure of neurons to Aβ is inhibited by gp91ds-tat, this study further demonstrates the important role of NADPH oxidase in producing the ROS that mediates the cytotoxic effects of Aβ. Thus besides providing an understanding of the molecular and cellular pathways whereby oligomeric Aβ conveys toxic effects and impairs neuronal function, this study further opens opportunities to target the NADPH oxidase pathway to ameliorate the Aβ effects. In the present study, we demonstrate the ability of EGCG to prevent Aβ-induced ROS accumulation and NMDA receptor dysfunction. These results suggest the possibility for use of other botanical antioxidants as well as dietary polyphenols for delaying the onset or retarding the progression of AD.
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